Literature DB >> 28913153

Quantitative analysis of 18F-NaF dynamic PET/CT cannot differentiate malignant from benign lesions in multiple myeloma.

Christos Sachpekidis1,2, Jens Hillengass3, Hartmut Goldschmidt3,4, Hoda Anwar1, Uwe Haberkorn1,5, Antonia Dimitrakopoulou-Strauss1.   

Abstract

A renewed interest has been recently developed for the highly sensitive bone-seeking radiopharmaceutical 18F-NaF. Aim of the present study is to evaluate the potential utility of quantitative analysis of 18F-NaF dynamic PET/CT data in differentiating malignant from benign degenerative lesions in multiple myeloma (MM). 80 MM patients underwent whole-body PET/CT and dynamic PET/CT scanning of the pelvis with 18F-NaF. PET/CT data evaluation was based on visual (qualitative) assessment, semi-quantitative (SUV) calculations, and absolute quantitative estimations after application of a 2-tissue compartment model and a non-compartmental approach leading to the extraction of fractal dimension (FD). In total 263 MM lesions were demonstrated on 18F-NaF PET/CT. Semi-quantitative and quantitative evaluations were performed for 25 MM lesions as well as for 25 benign, degenerative and traumatic lesions. Mean SUVaverage for MM lesions was 11.9 and mean SUVmax was 23.2. Respectively, SUVaverage and SUVmax for degenerative lesions were 13.5 and 20.2. Kinetic analysis of 18F-NaF revealed the following mean values for MM lesions: K1 = 0.248 (1/min), k3 = 0.359 (1/min), influx (Ki) = 0.107 (1/min), FD = 1.382, while the respective values for degenerative lesions were: K1 = 0.169 (1/min), k3 = 0.422 (1/min), influx (Ki) = 0.095 (1/min), FD = 1. 411. No statistically significant differences between MM and benign degenerative disease regarding SUVaverage, SUVmax, K1, k3 and influx (Ki) were demonstrated. FD was significantly higher in degenerative than in malignant lesions. The present findings show that quantitative analysis of 18F-NaF PET data cannot differentiate malignant from benign degenerative lesions in MM patients, supporting previously published results, which reflect the limited role of 18F-NaF PET/CT in the diagnostic workup of MM.

Entities:  

Keywords:  18F-NaF; PET/CT; SUV; degenerative joint disease; multiple myeloma; two-tissue compartment model

Year:  2017        PMID: 28913153      PMCID: PMC5596317     

Source DB:  PubMed          Journal:  Am J Nucl Med Mol Imaging


  36 in total

1.  The kinetics and reproducibility of 18F-sodium fluoride for oncology using current PET camera technology.

Authors:  Karen A Kurdziel; Joanna H Shih; Andrea B Apolo; Liza Lindenberg; Esther Mena; Yolanda Y McKinney; Stephen S Adler; Baris Turkbey; William Dahut; James L Gulley; Ravi A Madan; Ola Landgren; Peter L Choyke
Journal:  J Nucl Med       Date:  2012-06-22       Impact factor: 10.057

Review 2.  Molecular mechanisms of bone 18F-NaF deposition.

Authors:  Johannes Czernin; Nagichettiar Satyamurthy; Christiaan Schiepers
Journal:  J Nucl Med       Date:  2010-11-15       Impact factor: 10.057

3.  A JAVA environment for medical image data analysis: initial application for brain PET quantitation.

Authors:  K Mikolajczyk; M Szabatin; P Rudnicki; M Grodzki; C Burger
Journal:  Med Inform (Lond)       Date:  1998 Jul-Sep

4.  Differentiation of metastatic vs degenerative joint disease using semi-quantitative analysis with (18)F-NaF PET/CT in castrate resistant prostate cancer patients.

Authors:  Saima Muzahir; Robert Jeraj; Glenn Liu; Lance T Hall; Alejandro Munoz Del Rio; Timothy Perk; Christine Jaskowiak; Scott B Perlman
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-01-15

Review 5.  Current and future imaging modalities for multiple myeloma and its precursor states.

Authors:  Esther Tan; Brendan M Weiss; Esther Mena; Neha Korde; Peter L Choyke; Ola Landgren
Journal:  Leuk Lymphoma       Date:  2011-06-08

6.  Fluoride kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET.

Authors:  C Schiepers; J Nuyts; G Bormans; J Dequeker; R Bouillon; L Mortelmans; A Verbruggen; M De Roo
Journal:  J Nucl Med       Date:  1997-12       Impact factor: 10.057

7.  18F-sodium fluoride PET/CT in oncology: an atlas of SUVs.

Authors:  Nathanael Sabbah; Tatianie Jackson; Camila Mosci; Mehran Jamali; Ryogo Minamimoto; Andrew Quon; Erik S Mittra; Andrei Iagaru
Journal:  Clin Nucl Med       Date:  2015-04       Impact factor: 7.794

8.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

9.  Role of 18F-fluoride PET/CT in the assessment of multiple myeloma: initial experience.

Authors:  Yuji Nishiyama; Ukihide Tateishi; Kazuya Shizukuishi; Ayako Shishikura; Etsuko Yamazaki; Hiroto Shibata; Tomohiro Yoneyama; Yoshiaki Ishigatsubo; Tomio Inoue
Journal:  Ann Nucl Med       Date:  2012-08-23       Impact factor: 2.668

10.  Normal SUV values measured from NaF18- PET/CT bone scan studies.

Authors:  Aung Zaw Win; Carina Mari Aparici
Journal:  PLoS One       Date:  2014-09-25       Impact factor: 3.240

View more
  4 in total

Review 1.  Therapy-induced bone changes in oncology imaging with 18F-sodium fluoride (NaF) PET-CT.

Authors:  Najeeb Ahmed; Alyaa Sadeq; Fahad Marafi; Gopinath Gnanasegaran; Sharjeel Usmani
Journal:  Ann Nucl Med       Date:  2022-02-26       Impact factor: 2.668

2.  Prognostic significance of 18F-sodium fluoride in newly diagnosed multiple myeloma patients.

Authors:  Mahdi Zirakchian Zadeh; Siavash Mehdizadeh Seraj; Brian Østergaard; Stephanie Mimms; William Y Raynor; Mahmoud Aly; Austin J Borja; Leila S Arani; Oke Gerke; Thomas J Werner; Hongming Zhuang; Mona-Elisabeth Revheim; Niels Abildgaard; Poul Flemming Høilund-Carlsen; Abass Alavi
Journal:  Am J Nucl Med Mol Imaging       Date:  2020-08-25

3.  Can 18F-NaF PET/CT before Autologous Stem Cell Transplantation Predict Survival in Multiple Myeloma?

Authors:  Christos Sachpekidis; Annette Kopp-Schneider; Maximilian Merz; Anna Jauch; Marc-Steffen Raab; Hartmut Goldschmidt; Antonia Dimitrakopoulou-Strauss
Journal:  Cancers (Basel)       Date:  2020-05-23       Impact factor: 6.639

Review 4.  Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma.

Authors:  Christos Sachpekidis; Hartmut Goldschmidt; Antonia Dimitrakopoulou-Strauss
Journal:  Molecules       Date:  2019-12-29       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.